Super Early Scan of PSMA PET/CT in Evaluating Primary and Metastatic Lesions of Prostate Cancer
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patient Selection
2.2. Preparation of PCa Models
2.3. Measurement of Lipo-Hydro Partition Coefficient
2.4. 68Ga-PSMA-11 PET/CT
2.5. Image Interpretation of 68Ga-PSMA-11 PET/CT
2.6. Statistical Analysis
3. Results
3.1. Lipo-Hydro Partition Coefficient
3.2. Verification of Diagnostic Efficiency of PSMA PET in Model Mice
3.3. Clinical Findings of Super Early 68Ga-PSMA-11 PET
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Sample Availability
References
- Hofman, M.S.; Hicks, R.J.; Maurer, T.; Eiber, M. Prostate-specific membrane antigen PET: Clinical utility in prostate cancer, normal patterns, pearls, and pitfalls. Radiographics 2018, 38, 200–217. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hofman, M.S.; Murpy, D.G.; Williams, S.G.; Nzenza, T.; Herschtal, A.; Lourenco, R.D.A.; Bailey, D.L.; Budd, R.; Hicks, R.J.; Francis, R.J.; et al. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen(PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy(proPSMA study): Clinical trial protocol. BJU Int. 2018, 122, 783–793. [Google Scholar] [CrossRef] [PubMed]
- Afshar-Oromieh, A.; Babich, J.W.; Kratochwil, C.; Giesel, F.L.; Eisenhut, M.; Kopka, K.; Haberkorn, U. The rise of PSMA ligands for diagnosis and therapy of prostate cancer. J. Nucl. Med. 2016, 57, 79S–89S. [Google Scholar] [CrossRef] [Green Version]
- Perner, S.; Hofer, M.D.; Kim, R.; Shah, R.B.; Li, H.; Möller, P.; Hautmann, R.E.; Gschwend, J.E.; Kuefer, R.; Rubin, M.A. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum. Pathol. 2007, 38, 696–701. [Google Scholar] [CrossRef] [PubMed]
- Ho, C.L.; Wu, K.K.; Chen, S. Current status of PSMA PET imaging in prostate cancer. Asia-Pac. J. Clin. Oncol. 2020, 16, 7–11. [Google Scholar] [CrossRef]
- Feng, Y.Q.; Cui, B.P.; Wang, P.; Dai, W.L.; Deng, P.Y.; Tian, J.L. Research progress of 68Ga-PSMA PET/CT in the diagnosis of prostate cance. Chin. J. Nucl. Med. Mol. Imaging 2019, 39, 237–240. [Google Scholar]
- Backhaus, P.; Noto, B.; Avramovic, N.; Grubert, L.S.; Huss, S.; Bögemann, M.; Stegger, L.; Weckesser, M.; Schäfers, M.; Rahbar, K. Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives. Eur. J. Nucl. Med. Mol. Imaging 2018, 45, 860–877. [Google Scholar] [CrossRef]
- Schmidkonz, C.; Cordes, M.; Goetz, T.I.; Prante, O.; Kuwert, H.; Ritt, P.; Uder, M.; Wullich, B.; Goebell, P.; Bäuerle, T. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients. Ann. Nucl. Med. 2019, 33, 766–775. [Google Scholar] [CrossRef]
- Cardinale, J.; Schäfer, M.; Benešováet, M.; Bauder-Wüst, U.; Leotta, K.; Eder, M.; Neels, O.C.; Haberkorn, U.; Giesel, F.L.; Kopka, K. Preclinical evaluation of 18F-PSMA-1007, a new prostate-specific membrane antigen ligand for prostate cancer imaging. J. Nucl. Med. 2017, 58, 425–431. [Google Scholar] [CrossRef] [Green Version]
- Maurer, T.; Eiber, M.; Schwaiger, M.; Gschwend, J.E. Current use of PSMA-PET in prostate cancer management. Nat. Rev. Urol. 2016, 13, 226–235. [Google Scholar] [CrossRef]
- Solari, E.L.; Gafita, A.; Schachoff, S.; Bogdanović, B.; Asiares, A.V.; Amiel, T.; Hui, W.; Rauscher, I.; Visvikis, D.; Maurer, T.; et al. The added value of PSMA PET/MR radiomics for prostate cancer staging. Eur. J. Nucl. Med. Mol. Imaging 2022, 49, 527–538. [Google Scholar] [CrossRef] [PubMed]
- Giesel, F.L.; Will, L.; Lawal, I.; Lengana, T.; Kratochwil, C.; Vorster, M.; Neels, O.; Reyneke, F.; Haberkon, U.; Kopka, K.; et al. Intraindividual comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma: A pilot study. J. Nucl. Med. 2018, 59, 1076–1080. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wondergem, M.; Zant, F.M.; Broos, W.A.M.; Knol, R.J.J. Matched-Pair comparison of 18F-DCFPyL PET/CT and 18F-PSMA-1007 PET/CT in 240 prostate cancer patients: Interreader agreement and lesion detection rate of suspected lesions. J. Nucl. Med. 2021, 62, 1422–1429. [Google Scholar] [CrossRef] [PubMed]
- Ghadanfer, L.; Usmani, S.; Marafi, F.; Al-Kandari, F.; Rasheed, R. Incremental value of post diuretic 68Ga-PSMA-11 PET-CT in characterization of indeterminate lesions in prostate cancer. Asian Pac. J. Cancer Prev. 2020, 21, 3719–3727. [Google Scholar] [CrossRef] [PubMed]
- Trägårdh, E.; Enqvist, O.; Ulén, J.; Hvittfeldt, E.; Garpered, S.; Belal, S.L.; Bjartell, A.; Edenbrandt, L. Freely available artificial intelligence for pelvic lymph node metastases in PSMA PET-CT that performs on par with nuclear medicine physicians. Eur. J. Nucl. Med. Mol. Imaging 2022. [Google Scholar] [CrossRef]
- Harkirat, S.; Anand, S.S.; JAcob, M.J. Forced diuresis and dual-phase 18F-fluorodeoxyglucose-PET/CT scan for restaging of urinary bladder cancers. Indian J. Radiol. Imaging 2010, 20, 13–19. [Google Scholar] [CrossRef]
- Chang, C.T.; Liu, F.Y.; Tsai, J.J.; Lin, C.C.; Lee, C.C.; Kao, A. The clinical usefulness of dual phase 201Tl thyroid scan for false-negative fine-needle aspiration cytological diagnoses in non-functioning cold thyroid nodules. Anticancer Res. 2013, 23, 2965–2967. [Google Scholar]
- Uprimny, C.; Krioss, A.S.; Decristoforo, C.; Frita, J.; Warwitz, B.; Scarpa, L.; Roig, L.G.; Kendler, D.; Guggenberg, E.V.; Bektic, J.; et al. Early dynamic imaging in 68Ga-PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions. Eur. J. Nucl. Med. Mol. Imaging 2017, 44, 765–775. [Google Scholar] [CrossRef]
- Sasada, S.; Masumoto, N.; Suzuki, E.; Sueoka, S.; Goda, N.; Kajitani, K.; Emi, A.; Kadoya, T.; Okada, M. Prediction of biological characteristics of breast cancer using dual-phase FDG PET/CT. Eur. J. Nucl. Med. Mol. Imaging 2019, 46, 831–837. [Google Scholar] [CrossRef]
- Zhu, H.J.; Yang, B.; Dong, A.S.; Ye, H.M.; Cheng, C.; Pan, G.X.; Zuo, C.J. Dual-phase 99mTc-MIBI SPECT/CT in the characterization of enhancing solid renal tumors: A single-institution study of 147 cases. Clin. Nucl. Med. 2020, 45, 465–470. [Google Scholar] [CrossRef]
- Demirci, E.; Sahin, O.E.; Ocak, M.; Akovali, B.; Nematyazar, J.; Kabasakal, L. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging. Nucl. Med. Commun. 2016, 37, 1169–1179. [Google Scholar] [CrossRef]
- Rauscher, I.; Maurer, T.; Fendler, W.P.; Sommer, W.H.; Schwaiger, M.; Eiber, M. 68Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report. Cancer Imaging 2016, 16, 14. [Google Scholar] [CrossRef] [Green Version]
- Afshar-Oromieh, A.; Malcher, A.; Eder, M.; Eisenhut, M.; Linhart, H.G.; Hadaschik, B.A.; Holland-Letz, T.; Giesel, F.L.; Kratochwil, C.; Haufe, S.; et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: Biodistribution in humans and first evaluation of tumour lesions. Eur. J. Nucl. Med. Mol. Imaging 2013, 40, 486–495. [Google Scholar] [CrossRef] [PubMed]
- Kabasakal, L.; Demirci, E.; Ocak, M.; Akyel, R.; Nematyazar, J.; Aygun, A.; Halac, M.; Talat, Z.; Araman, A. Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. Nucl. Med. Commun. 2015, 36, 582–587. [Google Scholar] [CrossRef] [PubMed]
- Jahandideh, A.; Ståhle, M.; Virta, J.; Li, X.G.; Liljenbäck, H.; Miosoi, O.; Knuuti, J.; Roivainen, A.; Saraste, A. Evaluation of [68Ga]Ga-NODAGA-RGD for PET imaging of rat autoimmune myocarditis. Front. Med. 2021, 8, 783596. [Google Scholar] [CrossRef] [PubMed]
- Hu, K.; Shang, J.J.; Xie, L.; Hanyu, M.; Zhang, Y.D.; Zhang, Z.M.; Xu, H.; Wang, L.; Zhang, M.R. PET imaging of VEGFR with a novel 64Cu-labeled peptide. ACS Omega 2020, 5, 8508–8514. [Google Scholar] [CrossRef] [Green Version]
Items | Groups | Number or Value |
---|---|---|
Patients | - | 106 |
Radical prostatectomy | 25 | |
Age (years) | - | 67.1 (57–81) * |
Gleason score | NAN | 25 |
5 | 1 | |
6 | 2 | |
7 | 13 | |
8 | 18 | |
9 | 43 | |
10 | 4 | |
tPSA (ng/mL) ** | - | 2.47 (0.02–100) * |
Patients | Gleason Score | Metastatic Lesions at 45 Min P.I. | ||
---|---|---|---|---|
Size (cm) | Location | SUVmax_45 | ||
1 | 7 | 4.3 × 3.5 | right pelvic wall | 16.2 |
2 | 7 | 1.2 × 1.1 | pelvic lymph nodes | 3.6–5.2 |
3 | 8 | 1.9 × 1.5 | pelvic lymph nodes | 2.6–4.8 |
4 | 9 | 4.8 × 2.9 | left rectus abdominis | 3.5 |
5 | 9 | 6.1 × 5.6 | second lumbar vertebra | 5.3 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Mao, J.; Gao, M.; Cui, B.; Zhang, Y.; Wang, X.; Liang, S.; Zuo, C.; Chen, P.; Dong, A. Super Early Scan of PSMA PET/CT in Evaluating Primary and Metastatic Lesions of Prostate Cancer. Molecules 2022, 27, 4661. https://doi.org/10.3390/molecules27144661
Mao J, Gao M, Cui B, Zhang Y, Wang X, Liang S, Zuo C, Chen P, Dong A. Super Early Scan of PSMA PET/CT in Evaluating Primary and Metastatic Lesions of Prostate Cancer. Molecules. 2022; 27(14):4661. https://doi.org/10.3390/molecules27144661
Chicago/Turabian StyleMao, Juanli, Mingjun Gao, Bin Cui, Yingying Zhang, Xiaojiao Wang, Siyu Liang, Changjing Zuo, Peng Chen, and Aisheng Dong. 2022. "Super Early Scan of PSMA PET/CT in Evaluating Primary and Metastatic Lesions of Prostate Cancer" Molecules 27, no. 14: 4661. https://doi.org/10.3390/molecules27144661
APA StyleMao, J., Gao, M., Cui, B., Zhang, Y., Wang, X., Liang, S., Zuo, C., Chen, P., & Dong, A. (2022). Super Early Scan of PSMA PET/CT in Evaluating Primary and Metastatic Lesions of Prostate Cancer. Molecules, 27(14), 4661. https://doi.org/10.3390/molecules27144661